{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:34:19Z","timestamp":1779312859610,"version":"3.51.4"},"reference-count":32,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite new therapeutic options, treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD) remains challenging as organ involvement and clinical manifestations are highly variable. In previous trials of low-dose interleukin-2 (LD IL-2), we established the safety and efficacy of LD IL-2 for the treatment of SR-cGVHD. In the present report, we combined five phase 1 or 2 clinical trials conducted at our center to investigate organ-specific response rate, coinvolvement of organs, predictors of organ-specific response, and its possible association with immune response. For the 105 adult patients included in this report, the overall response rate after 8 or 12 weeks of LD IL-2 was 48.6% and 53.3%, including late responses in patients who continued treatment for extended periods. Skin was the most frequent organ involved (84%). The organ-specific response rate was highest in liver (66.7%) followed by the gastrointestinal tract (62.5%), skin (36.4%), joint\/muscle\/fascia (34.2%), and lung (19.2%). In multivariable analysis, shorter time from diagnosis of cGVHD to IL-2 initiation, shorter time from transplant to IL-2 initiation, and fewer prior therapies were associated with overall response as well as skin response. For immunologic correlates, the ratio of regulatory T cells:conventional T cells (ie, CD4Treg:CD4Tcon) ratio at 1 week was significantly higher in patients with overall and skin response; skin response was significantly associated with lower number of total CD3 T cells, CD4Tcon cells, and CD8 T cells and a higher number of B cells. For lung responders, terminal effector memory cell counts were lower within all T-cell populations compared with nonresponders. Organ-specific mechanisms of injury should be investigated, and organ-specific targeted therapies need to be developed.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007773","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T20:53:14Z","timestamp":1653598394000},"page":"4392-4402","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-6849","authenticated-orcid":false,"given":"Haesook T.","family":"Kim","sequence":"first","affiliation":[{"name":"1Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-2532","authenticated-orcid":false,"given":"Jennifer","family":"Whangbo","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol G.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Stowe","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"issue":"26","key":"2022072915261909100_B1","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"2022072915261909100_B2","doi-asserted-by":"crossref","first-page":"e149296","DOI":"10.1172\/JCI149296","article-title":"Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease","volume":"131","author":"Soci\u00e9","year":"2021","journal-title":"J Clin Invest."},{"issue":"2","key":"2022072915261909100_B3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"15","key":"2022072915261909100_B4","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv."},{"issue":"13","key":"2022072915261909100_B5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2017-11-784017","article-title":"B-cell targeting in chronic graft-versus-host disease","volume":"131","author":"Zeiser","year":"2018","journal-title":"Blood."},{"issue":"10","key":"2022072915261909100_B6","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.bbmt.2014.06.030","article-title":"Immunologic resolution of human chronic graft-versus-host disease","volume":"20","author":"Mahadeo","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2022072915261909100_B7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI41072","article-title":"Altered regulatory T cell homeostasis in patients with CD4+\u00a0lymphopenia following allogeneic hematopoietic stem cell transplantation","volume":"120","author":"Matsuoka","year":"2010","journal-title":"J Clin Invest."},{"issue":"8","key":"2022072915261909100_B8","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+\u00a0CD4+CD25+\u00a0regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood."},{"issue":"22","key":"2022072915261909100_B9","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med."},{"issue":"1","key":"2022072915261909100_B10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood."},{"issue":"17","key":"2022072915261909100_B11","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv."},{"issue":"7","key":"2022072915261909100_B12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/bloodadvances.2018029124","article-title":"Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease","volume":"3","author":"Belizaire","year":"2019","journal-title":"Blood Adv."},{"key":"2022072915261909100_B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006625","article-title":"A phase 1 study of donor regulatory T cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-versus-host disease","author":"Whangbo","journal-title":"Blood Adv."},{"issue":"3","key":"2022072915261909100_B14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report","volume":"12","author":"Pavletic","year":"2006","journal-title":"Biol Blood Marrow Transplant."},{"issue":"15","key":"2022072915261909100_B15","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood."},{"issue":"3","key":"2022072915261909100_B16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022072915261909100_B17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"2022072915261909100_B18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant."},{"issue":"21","key":"2022072915261909100_B19","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood."},{"issue":"10","key":"2022072915261909100_B20","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"17","key":"2022072915261909100_B21","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022072915261909100_B22","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood."},{"issue":"3","key":"2022072915261909100_B23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med."},{"issue":"22","key":"2022072915261909100_B24","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1182\/bloodadvances.2021005286","article-title":"Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival","volume":"5","author":"Pidala","year":"2021","journal-title":"Blood Adv."},{"issue":"12","key":"2022072915261909100_B25","doi-asserted-by":"crossref","first-page":"990.e1","DOI":"10.1016\/j.jtct.2021.08.017","article-title":"Ibrutinib in steroid-refractory chronic graft-versus-host disease, a single-center experience","volume":"27","author":"Chin","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"9","key":"2022072915261909100_B26","doi-asserted-by":"crossref","first-page":"777.e1","DOI":"10.1016\/j.jtct.2021.06.002","article-title":"Long-term follow-up of ruxolitinib in the treatment of steroid-refractory chronic graft-versus-host disease","volume":"27","author":"Ferreira","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"2022072915261909100_B27","doi-asserted-by":"crossref","first-page":"43.e1","DOI":"10.1016\/j.jtct.2021.10.015","article-title":"Efficacy and safety of ruxolitinib in steroid-refractory\/dependent chronic graft-versus-host disease: real-world data and challenges","volume":"28","author":"Redondo","year":"2022","journal-title":"Transplant Cell Ther."},{"issue":"5","key":"2022072915261909100_B28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1084\/jem.171.5.1509","article-title":"Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors","volume":"171","author":"Caligiuri","year":"1990","journal-title":"J Exp Med."},{"issue":"18","key":"2022072915261909100_B29","doi-asserted-by":"crossref","first-page":"e89278","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight."},{"issue":"68","key":"2022072915261909100_B30","doi-asserted-by":"crossref","first-page":"eabi6112","DOI":"10.1126\/sciimmunol.abi6112","article-title":"Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability","volume":"7","author":"Fumagalli","year":"2022","journal-title":"Sci Immunol."},{"issue":"16","key":"2022072915261909100_B31","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","article-title":"Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease","volume":"113","author":"Sarantopoulos","year":"2009","journal-title":"Blood."},{"issue":"5","key":"2022072915261909100_B32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/15\/4392\/1910715\/advancesadv2022007773.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/15\/4392\/1910715\/advancesadv2022007773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:52:17Z","timestamp":1659109937000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/15\/4392\/485387\/Organ-specific-response-after-low-dose-interleukin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":32,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,8,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007773","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]}}}